Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma.
1. What are the most important unmet needs in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)? (0:11)
2. What do you consider the most promising treatments in clinical development for relapsed/refractory CLL? (0:51)
3. Can we predict in advance who is at high-risk to relapse and then modify therapy for these high-risk patients? (1:42)
4. What have been the most exciting recent developments in the treatment of diffuse large B-cell lymphoma (DLBCL)? (2:34)
5. What are the most exciting developments in the frontline treatment of follicular lymphoma? (3:26)
Speaker disclosures: Ian W Flinn has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
